Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine + remifentanil versus propofol + remifentanil for painless gastroscopy
ChiCTR2200056591Phase 4Completed
- Sponsor
- People's Hospital of Jiangdu
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine, remifentanil and propofol (2 arms), sponsored by People's Hospital of Jiangdu. Primary endpoints: Sedation success rate, Sedation induction time and 5 more. Started Mar 2022; status: completed.
02
Drugs
esketamineremifentanilpropofol
Beyond the preview
Go deeper on ChiCTR2200056591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056591.